Medical Advocates
Pegylated Interferons
    Hepatitis C

Peg Interferon Alfa 2a
Peg Interferon Alfa 2b
 General Reports
Safety
Viral Dynamics
Efficacy Studies
 Adverse Events
Quality of Life
 Adherence

 

  
Peg Interferons Main Page Main New/Newsworthy  Home Page
Last Update:  May 09, 2012
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
     
     Journal Papers, Abstracts, and Commentaries
 
 
Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance
treatment.Neukam K, Mira JA, Gilabert I,  et al
Eur J Clin Microbiol Infect Dis. 2011 Oct 6
 Abstract

Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster
Recovery of CD4+ Cell Counts During and After Pegylated Interferon Plus Ribavirin
Therapy in HIV-Hepatitis C Virus Coinfected Patients.
Reiberger T, Payer BA, Kosi L,  et al
J Infect Dis. 2011 Jun;203(12):1802-1806.
 Abstract

Risk factors for infection during treatment with peginterferon alfa and ribavirin
for chronic hepatitis C.
 Roomer R, Hansen BE, Janssen HL, de Knegt RJ.
Hepatology. 2010 Jul 29
 Abstract

Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C.
Zhao S, Liu E, Wei K, Wang Y, et al
Eur J Clin Microbiol Infect Dis. 2010 Sep 9.
Abstract

Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization
of treatment duration according to on-treatment virologic response.
Zeuzem S, Poordad F.
Curr Med Res Opin. 2010 Jul;26(7):1733-43
 Abstract

Meta-analysis of factors associated with sustained viral response in patients on
hemodialysis treated with standard or pegylated interferon for hepatitis C infection.
 Alavian SM, Tabatabaei SV.
Iran J Kidney Dis. 2010 Jul;4(3):181-94.
 Abstract

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg-Interferon
{alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia.
Saadoun D, Resche Rigon M, et al
Blood. 2010 May
 Abstract

Prevalence and impact of occult hepatitis B infection in chronic hepatitis C
patients treated with pegylated interferon and ribavirin.
 Levast M, Larrat S, Thelu MA,  et al  
J Med Virol. 2010 Mar 24;82(5):747-754.
 Abstract

Ability of treatment week 12 viral response to predict long-term outcome in
genotype 1 hepatitis C virus/HIV coinfected patients.
Van den Eynde E, Tiraboschi JM, Tural C, et al
AIDS. 2010 Mar 17.
 Abstract

Pegylated Interferon and Ribavirin Promote Early Evolution of Nonstructural 5A Protein in
Individuals with Hepatitis C Who Demonstrate a Response to Treatment
Jain MK, Yuan HJ, Adams-Huet B, et al  
J Infect Dis. 2009 Aug 12
 Abstract

Meta-analysis on peginterferon plus ribavirin in treatment of hepatitis C virus genotype 1 or 4 infection in HIV patients.
Zhao SH, Liu EQ, Cheng DX, et al 
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 May;38(3):315-9.
Abstract

Peg-Interferon in Acute and Chronic Hepatitis C: A Review.
 Palumbo E.
Am J Ther. 2009 May 8.
Abstract

Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to
Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral Load.
Mizuta T, Kawaguchi Y, Eguchi Y,et al  
Dig Dis Sci. 2009 Jan 30
 Abstract
 
Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine
maintenance therapy.
 Belfiori B, Ciliegi P, Chiodera A, et al
Dig Liver Dis. 2008 Oct 18.
Abstract
 
Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection
Kang MJ, Jung EU, Park SW, et al
 Korean J Hepatol. 2008 Sep;14(3):318-30.
 Abstract
 
In vivo interferon system assessed by 2'-5' oligoadenylate synthetase activity in chronic hepatitis C
virus patients treated with pegylated interferon and ribavirin.
 Shindo M, Hamada K, Morikawa T, et al  
Hepatol Res. 2008 Aug 18.
 Abstract
 
Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin.
 Fung J, Lai CL, Hung I, et al  
J Infect Dis. 2008 Jul 25.
 Abstract
 
Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C.
 Gambarin-Gelwan M, Jacobson IM.
J Viral Hepat. 2008 Jul 10.
 Abstract
 
Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients.
Zhao S, Cheng D, Liu E, et al
Eur J Clin Microbiol Infect Dis. 2008 Jun 17.
Abstract
 
Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist?
 Tarantino G, Gagliardi G, Conca P.  
Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):467-9.
 Abstract
 
Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient
With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells.
Colombatto P, Ciccorossi P, Maina A, et al
Clin Pharmacol Ther. 2008 Mar 12
 Abstract
 
Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative
treatment.
Almasio PL, Cottone C, D'Angelo F.
Dig Liver Dis. 2007 Sep;39 Suppl 1:S88-95.
Abstract
 
Mutations in the interferon sensitivity determining region (NS5A aa 2209-2248) in patients with
hepatitis C 1b infection and correlating response to combined therapy of pegylated interferon
and ribavirin.
 Yen YH, Hung CH, Hu TH, et al  
 Aliment Pharmacol Ther. 2007 Oct 26;
 Abstract
 
Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves
virological outcomes.
Kevans D, Farrell G, Hopkins S, et al
 Haemophilia. 2007 Sep;13(5):593-598.
Abstract 
 
Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother
under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first
16 weeks of pregnancy.
 Labarga P, Pinilla J, Cachorro I, Del Prado YR.
 Reprod Toxicol. 2007 Jul 7;
Abstract 
 
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic
hepatitis C: a systematic review and economic evaluation.
 Shepherd J, Jones J, Hartwell D, et al
 Health Technol Assess. 2007 Mar;11(11):1-224
 Abstract
 
Emerging strategies for pegylated interferon combination therapy.
 Schiff ER.  
Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4 Suppl 1:S17-21.
 Abstract
 
Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today,
tomorrow and in the future.
Ferenci P.
Minerva Gastroenterol Dietol. 2006 Jun;52(2):157-74
 Abstract 
 
Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living
donor liver transplant recipients with hepatitis C.
Taniguchi M, Furukawa H, Shimamura T, et al
Transplantation. 2006 Jun 27;81(12):1747-9.
 Abstract

Pegylation of interferon alfa: structural and pharmacokinetic properties.
Pedder SC.
Semin Liver Dis. 2003;23 Suppl 1:19-22
 Abstract

     Conference Reports, Abstracts, and Posters 

  Anti golgi complex antibodies during pegylated interferon therapy for hepatitis c:
what does it mean?
Paraná R., Schinoni M., Codes L, et al
 (12th International Symposium on Viral Hepatitis and Liver Disease)
 Abstract
Safety
     

     Journal Papers, Abstracts, and Commentaries

  Safety of peginterferon in the treatment of chronic hepatitis C.
 Hashemi N, Rossi S, Navarro VJ, Herrine SK.
Expert Opin Drug Saf. 2008 Nov;7(6):771-81
Abstract
Viral Dynamics
     

Peg Interferons/Ribavirin

     Journal Papers, Abstracts, and Commentaries

 
Extending Combination Therapy with Peginterferon plus Ribavirin for Genotype 2 Chronic
Hepatitis C Virological Responders: A Pilot Study of 7 Cases.
Akuta N, Suzuki F, Arase Y,  et al 
Intervirology. 2010 Mar 3;53(3):188-192
 Abstract

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy
in chronic hepatitis C patients using viral and host factors.
 Shirakawa H, Matsumoto A, Joshita S, et al
 Hepatology. 2008 Jul 24
 Abstract
 
FULL-TEXT PDF ARTICLE
 Suitable treatment period in patients with virological response during combination therapy
of peginterferon and ribavirin for chronic hepatitis C.
 Arase Y, Suzuki F, Sezaki H, et al
Intern Med. 2008;47(14):1301-7.
 Paper


Predictors of viral kinetics to peginterferon plus ribavirin combination therapy
in Japanese patients infected with hepatitis C virus genotype 1b.
 Akuta N, Suzuki F, Kawamura Y, et al
 J Med Virol. 2007 Nov;79(11):1686-95.
Abstract

  Journal Papers, Abstracts, and Commentaries

  Predicting sustained virological response in chronic hepatitis C patients treated with
pegylated interferon and ribavirin using a novel highly sensitive Real-time detection
PCR assay
 Matsuura K, Tanaka Y, Takagi K,
Rinsho Byori. 2007 Nov;55(11):983-8
Abstract
Diagnostics
     

     Journal Papers, Abstracts, and Commentaries

  Predicting sustained virological response in chronic hepatitis C patients treated with
pegylated interferon and ribavirin using a novel highly sensitive Real-time detection
PCR assay
 Matsuura K, Tanaka Y, Takagi K,
Rinsho Byori. 2007 Nov;55(11):983-8
 Abstract
Efficacy (General Reports)
     
Peg Interferon Monotherapy
 
     Journal Papers, Abstracts, and Commentaries
 
 
Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon {alpha}
 Wiegand J, Deterding K, Cornberg M, Wedemeyer H.
 J Antimicrob Chemother. 2008 Sep 5
 Abstract 
 

Pegylated interferon treatment of acute pericarditis associated with acute hepatitis C.
Kocaman O, Aygün C, Konduk T, et al
Turk J Gastroenterol. 2007 Dec;18(4):268-271.
 Abstract 
 
Peg Interferon/Ribavirin
 
     Journal Papers, Abstracts, and Commentaries
 
 
Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: |
A meta-analysis of two large prospective clinical trials.
D'Heygere F, George C, Van Vlierberghe H,  et al
J Med Virol. 2011 May;83(5):815-9.

Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late
viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated
interferon and ribavirin.
Parikh M, Singh A, Sood G.
J Viral Hepat. 2010 Oct 18. doi: 10.1111
 Abstract

FULL-TEXT ARTICLE
 Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral
response in liver transplant patients with recurrent hepatitis C viral infection.
 Singhal A, Jain AB, Burke M, Black M.
Exp Clin Transplant. 2010 Sep;8(3):214-9.
 Paper

 Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related
Cirrhosis: Outcomes and Factors Predicting Response.
 Fernández-Rodríguez CM, Alonso S, Martinez SM,  et al
Am J Gastroenterol. 2010 Aug 10
 Abstract

Thyroid Function Outcomes Following Pegylated Interferon-alpha
and Ribavirin Therapy For Chronic Hepatitis C.
 Tran HA, Reeves GE, Ianna EA, Leembruggen N.  
Endocr Pract. 2010 May 3:1-16
 Abstract

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg-Interferon
{alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia.
 Saadoun D, Resche Rigon M, et al
Blood. 2010 May
Abstract

Hepatitis: Treatment of chronic hepatitis C-how much interferon is enough?
 Ferenci P.
 Nat Rev Gastroenterol Hepatol. 2010 Apr;7(4):191-3
 Abstract

Similar Treatment Response to Peginterferon and Ribavirin in Asian and Caucasian Patients With
Chronic Hepatitis C.
 Vutien P, Nguyen NH, Trinh HN, et  al  
 Am J Gastroenterol. 2009 Nov 10.
 Abstract

Equally Poor Outcomes to Pegylated Interferon-based Therapy in African Americans and
Hispanics With Chronic Hepatitis C Infection.
 Satapathy SK, Lingisetty CS, Proper S,  et al
J Clin Gastroenterol. 2009 Oct 12
 Abstract

An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients
referred for liver transplant.
 Massoumi H, Elsiesy H, Khaitova V, et al
Transplantation. 2009 Sep 15;88(5):729-35.
 Abstract

Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese
patients with chronic hepatitis C.
 Zhao SH, Chu YL, Cheng DX, Waqar AB, et al 
Int J Clin Pract. 2009 Sep;63(9):1334-
 Abstract

Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human
Immunodeficiency Virus.
 Gluud LL, Marchesini E, Iorio A.
Am J Gastroenterol. 2009 Jun 9
 Abstract

Patients achieving clearance of HCV with interferon therapy recover from decreased
retinol-binding protein 4 levels.
 Iwasa M, Hara N, Miyachi H, Tanaka H, et al     
 J Viral Hepat. 2009 Mar 3.
Abstract

FULL-TEXT PDF ARTICLE
 Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype
1b and low-virus load.
 Arase Y, Suzuki F, Akuta N, Sezaki H, et al   
Intern Med. 2009;48(5):253-8
Paper
 
A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination
therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV "
core region as predictor of sustained virological response.
Akuta N, Suzuki F, Hirakawa M, et al
 J Med Virol. 2009 Mar;81(3):452-8
 Abstract
 
Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C:
A systematic review and meta-analysis.
 Hartwell D, Shepherd J
Int J Technol Assess Health Care. 2009 Winter;25(1):56-62.
 Abstract
 
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin
in a methadone maintenance treatment program.
 Litwin AH, Harris KA Jr, Nahvi S,
J Subst Abuse Treat. 2008 Nov 25.
 Abstract
 
The effect of body weight reduction on the effectivity of combined peginterferon and ribavirin treatment
in chronic HCV hepatitis.
Hagymási K, Fehér J
Orv Hetil. 2008 Nov 16;149(46):2189-92
 Abstract
 
Pegylated Interferon plus Ribavirin Combination Therapy for Chronic Hepatitis C in Patients with Congenital
Coagulation Disorders.
 Katsarou O, Theodosiades G, Ioannidou P, et al
 Acta Haematol. 2008 Oct 1;120(2):63-69.
 Abstract
 
Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection.
 Kang MJ, Jung EU, Park SW, et al  
 Korean J Hepatol. 2008 Sep;14(3):318-30.
 Abstract
 
Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients
with Recurrent Hepatitis C Infection.
 Veldt BJ, Poterucha JJ, Watt KD, et al  
Am J Transplant. 2008 Aug 22.
 Abstract
 
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C
due to genotype 4.
 Martín-Carbonero L, Puoti M, et al
 J Viral Hepat. 2008 Jul 10.
 Abstract
 
Effectiveness of the combined interferon and ribavirin therapy in hepatitis C virus infection in patient
with hypertension and kidney function disorder.
 Bátyi E, Szegedi J.
Orv Hetil. 2008 May 8;149(19):889-92.
 Abstract 
 
Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in
clinical practice: a 5-year experience.
 Vergara M, Gallach M, Dalmau B, et al 
Gastroenterol Hepatol. 2008 May;31(5):274-9.
 Abstract 

Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin
for Chronic Hepatitis C.
 Arase Y, Suzuki F, Sezaki H 
Intervirology. 2008 Feb 29;51(1):1-6
Abstract 
 
Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic
Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with
Pegylated Interferon-alpha and Ribavirin. A Prospective Randomized Controlled Trial.
Takaki S, Kawakami Y, Imamura M, Aikata  
Intervirology. 2008 Feb 4;50(6):439-446 [
 Abstract 
 
Baseline CD4 Cell Count and Outcome of Pegylated Interferon Plus Ribavirin Therapy in
HIV/Hepatitis C Virus-Coinfected Patients.
 Valerio L, Yazdanpanah Y, Poizot-Martin I, et al
 J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):50-55.
Abstract 
 
Treatment of acute hepatitis C in an HIV-positive man with pegylated interferon and ribavirin
for 24 weeks.
Rafiq N, Carriero D, Uriel A, Dieterich DT.
AIDS Read. 2007 Nov;17(11):561-4.
 Abstract 
 
Treatment With Pegylated Interferon and Ribavirin for Hepatitis C Virus-associated Severe
Cryoglobulinemia in a Liver/Kidney Transplant Recipient.
 Montalbano M, Pasulo L, Sonzogni A, et al
 J Clin Gastroenterol. 2007 Feb;41(2):216-220.
 Abstract 
 
Pegylated Interferon and Ribavirin Failures: Is Retreatment an Option?
 Cheruvattath R, Rosati MJ, Gautam M, et al  
Dig Dis Sci. 2007 Jan 26;
Abstract 
 
Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated
with ribavirin and thalidomide: report of six cases of total remission.
 Caseiro MM.  
Rev Inst Med Trop Sao Paulo. 2006 Mar-Apr;48(2):109-12.
Abstract 
 
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients
coinfected with HIV and HCV genotype 1.
 Patel MR, Mullen MP, Dieterich DT. et al 
AIDS Read. 2006 Mar;16(3):164, 168-9;
 Abstract 
 
Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C
in African Americans: results in treatment-naive patients in a university liver clinic.
 Srivastava S, Bertagnolli M, Lewis JH.   
J Natl Med Assoc. 2005 Dec;97(12):1703-7.
 Abstract 
 
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection.
 Legrand-Abravanel F, Nicot F ,Boulestin A, et al
 J Med Virol. 2005 Sep;77(1):66-9.
 Abstract 

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
 Fried MW, Hadziyannis SJ.
 Semin Liver Dis. 2004 May;24 Suppl 2:47-54.
Abstract 

Current status of the use of growth factors and other adjuvant medications in patients
receiving peginterferon and ribavirin.
Kontorinis N, Agarwal K, Dieterich DT. et al
 Rev Gastroenterol Disord. 2004;4 Suppl 1:S39-47
 Abstract

 

     Conference Reports, Abstracts, and Posters 
 
 
Long-term outcomes after peg-IFN plus ribavirin in HIV/HCV-cirrhotic patients with hypersplenism undergoing
partial splenic embolization (PSE)
 A. Moreno, R. Bárcena, C. Quereda
(XVII International AIDS Conference)
 Abstract
 
HCV relapses upon completion of peg-interferon plus ribavirin in HIV-infected patients: rate,
 iming and predictors
 P. Barreiro, M. Nuñez, I. Santos, et al
(XVII International AIDS Conference)
 Abstract
 
POSTER
Rapid Virological Response at Week 4 Predicts Sustained Response to Pegylated
Interferon + Ribavirin among HIV/HCV-co-Infected Patients
JA Mira, B Valera-Bestard, A Arizcorreta-Yarza, et al
 PDF Poster     Abstract
 
Treatment of Spanish HIV-infected Patients with Recurrent Hepatitis C Virus after Liver
Transplantation with Pegylated Interferon + Ribavirin: Preliminary Results of the FIPSE
OLT-HIV-05 - GESIDA 45-05 Cohort Study
JM Miro, M Montejo, L Castells, et al
 (14 CROI)
 Abstract
 
aNadir CD4 Count Does Not Predict Response to Pegylated Interferon and Ribavirin in
HIV/HCV-co-infected Patients
S Hopkins. O Barry, J Turner, et al
 (13 CROI)
Abstract
 
POSTER
Effect of HIV Co-infection and Treatment with Pegylated Interferon + Ribavirin on Hepatitis C
Virus-specific Immune Responses
L Capa, V Soriano, J García-Samaniego, et al
 (13 CROI)
 PDF Poster     Abstract
 
POSTER
Predictive Value of Early Virological Response to Treatment with Interferon-base Regimens
Plus Ribavirin in HIV Patients with Chronic Hepatitis C
 M Laguno, M Larrousse, J Murillas, et al
 (13 CROI)
 PDF Poster   Abstract

Treatment combination with pegylated-interferon and ribavirin in chronic hepatitis
of HIV-HCV coinfected patients
I Santos, J P Zabaleta, D A Rodríguez-Serrano,  et al;
 (15IAC)
 Abstract
Quality of Life
     

     Journal Papers, Abstracts, and Commentaries

  Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life.
Nayman Alpat S, Usluer G, Yavuz H
J Chemother. 2008 Feb;20(1):101-5. L
Abstract
Adherence
 

     Journal Papers, Abstracts, and Commentaries

  Hepatitis C patients' self-reported adherence to pegylated interferon and ribavirin.
Weiss JJ, Bhatti L, Dieterich DT, et al
Aliment Pharmacol Ther. 2008 Apr 16
Abstract

Peg Interferons Main Page Main New/Newsworthy  Home Page

Pegylated Interferons
Hepatitis C